Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis

European Journal of Cancer Care

Volumn 17, Issue 5, 2008, Pages 431-443

  Machado Rocha, F C ^a,b   Stefano S C ^a   De Cassia Haiek R ^a   Rosa Oliveira, L M Q ^a   Da Silveira, D X ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cancer; Cannabis; Chemotherapy; Meta analysis; Randomized clinical trial; Systematic review

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CANNABINOID; CANNABIS; NEUROLEPTIC AGENT;

CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; META ANALYSIS; NAUSEA; NEOPLASM; REVIEW; TREATMENT OUTCOME; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTIPSYCHOTIC AGENTS; CANNABINOIDS; CANNABIS; FEMALE; HUMANS; MALE; NAUSEA; NEOPLASMS; TREATMENT OUTCOME; VOMITING;

EID: 50349086035     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2008.00917.x     Document Type: Review

References (87)

1. Abrahamov A., Abrahamov A. Mechoulam R. (1995) An efficient new cannabinoid anti-emetic in pediatric oncology. Life Sciences 56, 2097 2102.
2. Adams I.B. Martin B.R. (1996) Cannabis: pharmacology and toxicology in animals and humans. Addiction 91, 1585 1614.
3. Ahmedzai S., Carlyle D.L., Calder I.T. Moran F. (1983) Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. British Journal of Cancer 48, 657 663.
4. Anti-emetic Subcommitee of the Multinational Association of Supportive Care in Cancer (MASCC 1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Annals of Oncology 9, 1022 1029.
5. Barowski M.T. (1984) Advances in anti-emetic therapy. Cancer Treatment Reviews 11, 237 256.
6. Bonnie R.J. Whitebread C.H., I.I. (1974) The Marijuana Conviction: A History of Marijuana Prohibition in the United States. University Press of Virginia, Charlottsville, VA, USA.
7. Chan H.S., Correia J.A. MacLeod S.M. (1987) Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79, 946 952.
8. Chang A.E., Shiling D.J., Stillman R.C., Goldberg N.H., Seipp C.A., Barofsky I. et al. (1979) Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Annals of Internal Medicine 91, 819 824.
9. Chang A.E., Shiling D.J., Stillman R.C., Goldberg N.H., Seipp C.A., Barofsky I. et al. (1981) A prospective evaluation of delta-9- tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47, 1746 1751.
10. Citron M.L., Herman T.S., Vreeland K., Krasnow S.H., Fossieck B.E., Jr Harwood Franklin R. Cohen M.H. (1985) Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treatment Report 69, 109 112.
11. Colls B.M. (1980) Cannabis and cancer chemotherapy. Lancet i, 1187 1188.
12. Colls B.M., Ferry D.G., Gray A.J., Harvey V.J. McQueen E.G. (1980) The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. The New Zealand Medical Journal 91, 449 451.
13. Cone L.A., Greene D.S. Helm N.A. (1982) Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. Cancer Treatment Reviews 9 (Suppl. B 63 70.
14. Crawford S.M. Buckman R. (1986) Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinun: a double blind study. Medical Oncology and Tumor Pharmacotherapy 3, 39 42.
15. Cronin C.M., Sallan S.E., Gelber R., Lucas V.S. Laszlo J. (1981) Anti-emetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. Journal of Clinical Pharmacology 21, 43S 50S.
16. Cunningham D., Forrest G.J., Soukop M., Gilchrest N.L. Calder I.T. (1985) Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. British Medical Journal 291, 864 865.
17. Cunningham D., Bradley C.J., Forrest G.J., Hutcheon A.W., Adams L., Sneddon M., Harding M., Herr D.J., Soukop M. Kaye S.B. (1988) A randomised trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. European Journal of Cancer Clinical Oncology 24, 685 689.
18. Dalzell A.M., Bartlett H. Lilleyman J.S. (1986) Nabilone: an alternative anti-emetic for cancer chemotherapy. Archives of Disease in Childhood 61, 502 505.
19. Darmani N.A. (2001) Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB (1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24, 198 203.
20. Devine M.L., Dow G.J., Greenberg B.R., Holsten D.W., Icaza L., Jue P.Y., Meyers F.H., O'Brien E., Roberts C.M., Rocchio G.L., Stanton W. Wesson D.R. (1987) Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. Clinical Pharmacology 6, 319 322.
21. Diasio R.B., Ettinger D.S. Satterwhite B.E. (1981) Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. Journal of Clinical Pharmacology 21, 81S 5S.
22. Dodds L.J. (1985) The control of cancer chemotherapy-induced nausea and vomiting. Journal of Clinical Hospital Pharmacology 10, 143 166.
23. Einhorn L. (1982) Nabilone: an effective anti-emetic agent in patients receiving cancer chemotherapy. Cancer Treatment Reviews 9, 55 61.
24. Einhorn L.H., Nagy C., Furnas B. Williams S.D. (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Journal of Clinical Pharmacology 21, 64 69S.
25. Ekert H., Waters D., Jurk I.H., Mobilia J. Loughnan P. (1979) Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Medical Journal of Australia 2, 657 659.
26. Felder C.C. Glass M. (1998) Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology and Toxicology 38, 179 200.
27. Ferrari F., Ottani A. Giuliani D. (1999) Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug. Pharmacological, Biochemistry and Behavior 62, 75 80.
28. Fiori J.J. Gralla R.J. (1984) Pharmacologic treatment of chemotherapy-induced nausea and vomiting. Cancer Investigation 2, 351 361.
29. Fritak S., Moertel C.G.O., Fallon J.R., Rubin J. Creagan E.T. (1979) Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Annals of Internal Medicine 91, 825 830.
30. Garb S., Beers A.L., Bograd M., McMahon R.T., Mangalik A., Ashmann A.C. Lenine S. (1980) Two-pronged study of tetrahydrocannabinol (THC) prevention of vomiting from cancer chemotherapy. IRCS Medical Science 8, 203 204.
31. George M., Pejovic M.H., Thuaire M., Kramar A. Wolff J.P. (1983) Randomised comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin. Biomedicine and Pharmacotherapy 37, 24 27.
32. Gilbert C.J., Ohly K.V., Rosner G. Peters W.P. (1995) Randomised, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based anti-emetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 76, 2330 2337.
33. Gralla R.J., Tyson L.B., Bordin L.A., Clark R.A., Kelsen D.P., Kris M.G. et al. (1984) Anti-emetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9- tetrahydrocannabinol. Cancer Treatment Report 68, 163 172.
34. Grotenhermen F. (2002a) Review of therapeutic effects. In : Pharmacology, Toxicology and Therapeutic Potential (eds Grotenhermen F. Russo E.), pp. 55 65. The Haworth Press, New York, USA.
35. Grotenhermen F. (2002b) Effects of cannabis and the cannabinoids. In : Pharmacology, Toxicology and Therapeutic Potential (eds Grotenhermen F. Russo E.), pp. 55 65. Xxxxxx, New York, USA.
36. Heim M.E., Romer W. Queisser W. (1981) Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. Journal of Clinical Pharmacology 21, 86S 89S.
37. Herman T.S., Einhorn L.H., Jones S.E., Nagy C., Chester A.B., Dean J.C. et al. (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England Journal of Medicine 300, 1295 1297.
38. Herstedt J. (1996) New perspective in antiemetic treatment. Support Care Cancer 4, 416 419.
39. Higi M., Niederle N., Bremer K., Schmitt G., Schmidt C.G. Seeber S. (1982) Levonantradol bei der Behandlung von zytostatika-bedingter Übelkeit und Erbrechen. Deutsche Medizinische Wochenschrift 107, 1232 1234.
40. Hutcheon A.W., Palmer J.B., Soukop M., Cunningham D., McArdle C., Welsh J. et al. (1983) A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. European Journal of Cancer Clinical Oncology 19, 1087 1090.
41. Jadad A., Moore A., Carrol D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J. et al. (1996) Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials 17, 1 12.
42. Johansson R., Kikku P. Groenroos M. (1982) A double-blind, controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treatment Reviews 9, 25 33.
43. Jones S.E., Durant J.R., Greco F.A. Robertone A. (1982) A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews 9, 45 48.
44. Karniol I.G. (2000) Cannabis sativa e derivados. In : Dependência de Drogas, (eds Seibel S.D. Toscano A. Jr), pp. 131 142. Atheneu, São Paulo, Brasil.
45. Kenny J.B. Wilkinson P.M. (1982) Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. Clinical Oncology 8, 335 339.
46. Kluin-Neleman J.C., Neleman F.A., Meuwissen O.J.A.T. Maes R.A.A. (1979) Delta-9-tetrahydrocannabinol (THC) as an antiemetic for patients receiving cancer chemotherapy; a double blind cross-over trial against placebo. Veterinary and Human Toxicology 21, 228 240.
47. Kris M.G., Gralla R.J., Clark R.A. et al. (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Journal of Clinical Oncology 3, 1379 1384.
48. Lane M., Smith F.E., Sullivan R.A. Plasse T.F. (1990) Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. American Journal of Clinical Oncology 13, 480 484.
49. Lane M., Vogel C.L., Ferguson J., Krasnow S., Saiers J.L., Hamm J. et al. (1991) Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management 6, 352 359.
50. Laszlo J., Lucas V.S., Hanson D.C., Cronin C.M. Sallan S.E. (1981) Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. Journal of Clinical Pharmacology 21, 51S 56S.
51. Levitt M. (1982) Nabilone vs placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treatment Reviews 9, 49 53.
52. Levitt M., Wilson W., Bowman D., Kemel S., Krepart G., Marks V., Schipper H., Thomson G., Weinerman B. Weinerman R. (1981) Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of Δ9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. Journal of Clinical Pharmacology 21, 103S 109S.
53. Lucas V.S. Laszlo J. (1980) Δ9-tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy. Journal of the American Medical Association 243, 1241 1243.
54. Lucraft H.H. Palmer M.K. (1982) Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clinical Radiology 33, 621 622.
55. Mallet P.E. Beninger R.J. (1996) The endogenous cannabinoid receptor agonist anandamide impairs memory in rats. Behavioral Pharmacology 7, 276 284.
56. McCabe M., Smith F.P., Macdonald J.S., Woolley P.V. Goldberg D. (1988) Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Investigational New Drugs 6, 243 246.
57. Moore R.A., Tramèr M.R., Carroll D., Wiffen P.J. McQuay H.J. (1998) Quantitative systematic review of topically-applied non-steroidal anti-inflamatory drugs. British Medical Journal 316, 333 338.
58. Mulrow C.S., Oxman A.D., eds. (1997) Cochrane Collaboration Handbook [updated September 1997]. In : The Cochrane Library, Update Software, Oxford, UK.
59. Neidhart J.A., Gagen M.M., Wilson H.E. Young D.C. (1981) Comparative trial of the antiemetic effects of THC and haloperidol. Journal of Clinical Pharmacology 21, 38 42S.
60. Niamatali C., Fallon S.D. Egan E.L. (1984) Nabilone in the management of prochlorperazine resistant cancer chemotherapy induced emesis. Irish Medical Journal 77, 276 277.
61. Niederle N., Schutte J. Schmidt C.G. (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klinische Wochenschrift 64, 362 365.
62. Niiranen A. Mattson K. (1987) Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. American Journal of Clinical Oncology 10, 325 329.
63. Olver I. (2004) Two decades of progress in treating chemotherapy induced emesis. Cancer Forum 28, 140 143.
64. Olver I., Pasta W., Derpierre A. et al. (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Annals of Oncology 7, 945 952.
65. Orr L.E. McKernan J.F. (1981) Antiemetic effect of Δ9- tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. Journal of Clinical Pharmacology 21, 76S 80S.
66. Pertwee R.G. (1990) The central neuropharmacology of psychotropic cannabinoids. In : Psychotropic Drugs of Abuse. (ed Balfour D.J.K.), pp. 355 429. Pergamon Press, New York, USA.
67. Pertwee R.G. (1999a) Evidence for the presence of CB1 cannabinoid receptors on peripheral neurons and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sciences 65, 597 605.
68. Pertwee R.G. (1999b) Pharmacology of cannabinoid receptor ligants. Current Medicinal Chemistry 6, 635 664.
69. Pomeroy M., Fennely J.J. Towers M. (1986) Prospective randomised double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemotherapy and Pharmacology 17, 285 288.
70. Rose M. (1980) Cannabis: a medical question? Lancet 1, 703.
71. Sallan S.E., Zinberg N.E., Frei E., 3rd (1975) Anti-emetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England Journal of Medicine 293, 795 797.
72. Sallan S.E., Cronin C., Zelen M. Zinberg N.E. (1980) Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of Medicine 302, 135 138.
73. Schwartzberg L.S. (2007) Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. Journal of Support Oncology 5, 5 12.
74. Sheidler V.R., Ettinger D.S., Diasio R.B., Enterline J.P. Brown M.D. (1984) Double-blind multiple-dose cross-over study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. Journal of Clinical Pharmacology 24, 155 159.
75. Stambaugh J.E., McAdams J. Vreeland F. (1984) Dose ranging evaluation of the antiemetic efficacy of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. Journal of Clinical Pharmacology 24, 480 485.
76. Steele N., Gralla R.J., Braun D.W., Jr. Young C.W. (1980) Double-blind comparison of the anti-emetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treatment Report 64, 219 224.
77. Sweet D.L., Miller N.J., Weddington W., Senay E. Sushelsky L. (1981) Δ9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A pilot study. Journal of Clinical Pharmacology 21, 70S 75S.
78. Tattersall F.D., Rycroft W., Hill R.G. Hargreaves R.J. (1994) Enatioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology 33, 259 260.
79. Tramèr M.R., Carroll D., Campbell F.A., Reynolds D.J.M., Moore R.A. McQuay H.J. (2001) Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. British Medical Journal 323, 1 8.
80. Tyson L.B., Gralla R.J., Clark R.A., Kris M.G., Bordin L.A., Bosl G.J 1985) Phase 1 trial of levonantradol in chemotherapy-induced emesis. American Journal of Clinical Oncology 8, 528 532.
81. Ungerleider J.T., Andrysiak T., Fairbanks L., Goodnight J., Sarna G. Jamison K. (1982) Cannabis and cancer therapy: a comparison of delta-9-THC and prochlorperazine. Cancer 50, 636 645.
82. Ungerleider J.T., Fairbanks L.A., Andrysiak T., Sarna G., Goodnight J. Jamison K. (1985) THC or compazine for the cancer chemotherapy patient - the UCLA study. Part II: patient drug preference. American Journal of Clinical Oncology 8, 142 147.
83. Vinciguerra V., Moore T. Brennan E. (1988) Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State Journal of Medicine 88, 525 527.
84. Wada J.K., Bogdon D.L., Gunnel J.C., Hum G.J., Gota C.H. Rieth T.E. (1982) Double-blind, randomised, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treatment Reviews 9, 39 44.
85. Walsh D., Nelson K.A. Mahmoud F.A. (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137 143.
86. Welsh J., Stuart F., Sangster G., Milstead R., Kaye S., Cash H., Charlton D. Calman K. (1983) Oral levonantradol in the control of cancer chemotherapy-induced emesis. Cancer Chemotherapy and Pharmacology 11, 66 67.
87. Wilcox P.M., Fetting J.H., Nettesheim K.M. et al. (1982) Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treatment Report 66, 1601 1604.